[Federal Register Volume 70, Number 125 (Thursday, June 30, 2005)]
[Notices]
[Pages 37862-37863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-12962]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Research Review Subcommittee of the Blood Products Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a subcommittee of a 
public advisory committee of the Food and Drug Administration (FDA). At 
least one portion of the meeting will be closed to the public.
    Name of Subcommittee: Research Review Subcommittee of the Blood 
Products Advisory Committee

[[Page 37863]]

    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on July 22, 2005, from 8 
a.m. to 5 p.m.
    Location: Holiday Inn Gaithersburg, Two Montgomery Village Ave., 
Gaithersburg, MD 20879.
    Contact Person: William Freas or Pearline K. Muckelvene, Center for 
Biologics Evaluation and Research, (HFM-71), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 3014519516. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: On July 22, 2005, the subcommittee will listen to 
presentations to further a dynamic, responsive, and cutting edge 
research program at the Office of Blood Research and Review, Center for 
Biologics Evaluation and Research (CBER), that facilitates development 
of safe and effective biological products. The subcommittee's 
recommendations will be publicly discussed at a future meeting of the 
Blood Products Advisory Committee. Information regarding CBER's 
scientific program is outlined in its Strategic Plan of 2004 and is 
available to the public on the Internet at: http://www.fda.gov/cber/inside/mission.htm. Information regarding FDA's Critical Path to New 
Medical Products is available to the public on the Internet at: http://www.fda.gov/oc/initiatives/criticalpath/.
    Procedure: On July 22, 2005, from 8 a.m. to 1:15 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the subcommittee. Written submissions may be made to the contact person 
by July 14, 2005. Oral presentations from the public will be scheduled 
between approximately 12:15 p.m. and 1:15 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person by July 14, 2005, and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Subcommittee Deliberations: On July 22, 2005, from 2:15 p.m. 
to 5 p.m., the meeting will be closed to the public. The meeting will 
be closed to permit discussion where disclosure would constitute a 
clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)) 
and to permit discussion and review of trade secret and/or confidential 
information (5 U.S.C. 552b(c)(4)). The subcommittee will discuss the 
internal research programs in the Office of Blood Research and Review, 
CBER.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact William Freas or 
Pearline K. Muckelvene at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 23, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-12962 Filed 6-29-05; 8:45 am]
BILLING CODE 4160-01-S